Cargando…
Vemurafenib induces a noncanonical senescence-associated secretory phenotype in melanoma cells which promotes vemurafenib resistance
More than one half melanoma patients have BRAF gene mutation. BRAF inhibitor vemurafenib is an effective medication for these patients. However, acquired resistance is generally inevitable, the mechanisms of which are not fully understood. Cell senescence and senescence-associated secretory phenotyp...
Autores principales: | Peng, Jianyu, Lin, Zijun, Chen, Weichun, Ruan, Jie, Deng, Fan, Yao, Lin, Rao, Minla, Xiong, Xingdong, Xu, Shun, Zhang, Xiangning, Liu, Xinguang, Sun, Xuerong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10345356/ https://www.ncbi.nlm.nih.gov/pubmed/37456058 http://dx.doi.org/10.1016/j.heliyon.2023.e17714 |
Ejemplares similares
-
Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib
por: Queirolo, Paola, et al.
Publicado: (2016) -
Metastatic melanoma and vemurafenib: novel approaches
por: De Mello, Ramon Andrade
Publicado: (2012) -
A STATement on Vemurafenib-Resistant Melanoma
por: Hartsough, Edward J., et al.
Publicado: (2013) -
The Tubulin Inhibitor VERU-111 in Combination With Vemurafenib Provides an Effective Treatment of Vemurafenib-Resistant A375 Melanoma
por: Cui, Hongmei, et al.
Publicado: (2021) -
Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma
por: Piejko, Karolina, et al.
Publicado: (2023)